Skip to content

Nasdaq · CIK 0001427925

TLPH TALPHERA, INC.

Insider trading from SEC Form 4. Last filing Mar 25, 2026. Close $1.08 on Oct 9, 2026, +50% from the 52-week low and -27% from the high.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
12
with a Form 4 at this company

Price and insider trades, last year

TLPHOct 9, 2026 · close 1.08

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at TALPHERA, INC., scored.

ScoreInsiderValueHoldingsPrice contextFiled
54ModerateVincent J. Angotti
CHIEF EXECUTIVE OFFICER
buy
$125k
213,310 shares
+36%+105% from low-45% from high
61NotableRaffi Asadorian
Chief Financial Officer
buy
$37k
45,000 shares
+97%+108% from low-45% from high
63NotableVincent J. Angotti
CHIEF EXECUTIVE OFFICER
buy
$86k
105,364 shares
+22%+108% from low-45% from high
53ModerateShakil Aslam
Chief Medical Officer
buy
$28k
35,000 shares
+73%+108% from low-45% from high
53ModerateVincent J. Angotti
CHIEF EXECUTIVE OFFICER
buy
$125k
213,310 shares
+112%+16% from low-50% from high
18WeakShakil Aslam
Chief Medical Officer
buy
$6,038
5,695 shares
+18%-
30WeakVincent J. Angotti
CHIEF EXECUTIVE OFFICER
buy
$3,200
5,000 shares
+2%-
22WeakRaffi Asadorian
Chief Financial Officer
sell
$119
155 shares
-0%-
25WeakVincent J. Angotti
CHIEF EXECUTIVE OFFICER
buy
$3,650
5,000 shares
+3%-

Transactions

The last 50 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Mar 13, 2026Vincent J. Angotti
CHIEF EXECUTIVE OFFICER
POpen-market purchase
Common Stock
+213,310$0.59$125k800,705Mar 25, 2026
Feb 10, 2026Vincent J. Angotti
CHIEF EXECUTIVE OFFICER
FTax withholding
Common Stock
-3,179$0.84$2,658481,590Feb 20, 2026
Feb 10, 2026Raffi Asadorian
Chief Financial Officer
FTax withholding
Common Stock
-958$0.84$80146,256Feb 20, 2026
Feb 12, 2026Shakil Aslam
Chief Medical Officer
POpen-market purchase
Common Stock
+35,000$0.81$28k83,178Feb 20, 2026
Feb 12, 2026Raffi Asadorian
Chief Financial Officer
POpen-market purchase
Commom Stock
+45,000$0.81$37k91,256Feb 20, 2026
Feb 12, 2026Vincent J. Angotti
CHIEF EXECUTIVE OFFICER
POpen-market purchase
Common Stock
+105,364$0.81$86k586,954Feb 20, 2026
Feb 12, 2026Shakil Aslam
Chief Medical Officer
AGrant or award
Stock Option (Right to Buy)derivative
+205,000$0.00$0205,000Feb 20, 2026
Feb 14, 2026Raffi Asadorian
Chief Financial Officer
FTax withholding
Common Stock
-2,933$0.79$2,32788,323Feb 20, 2026
Feb 14, 2026Vincent J. Angotti
CHIEF EXECUTIVE OFFICER
FTax withholding
Common Stock
-9,559$0.79$7,584577,395Feb 20, 2026
Feb 12, 2026Raffi Asadorian
Chief Financial Officer
AGrant or award
Stock Option (Right to Buy)derivative
+260,000$0.00$0260,000Feb 20, 2026
Feb 12, 2026Vincent J. Angotti
CHIEF EXECUTIVE OFFICER
AGrant or award
Stock Option (Right to Buy)derivative
+594,000$0.00$0594,000Feb 20, 2026
Oct 23, 2025Stephen J Hoffman
director
AGrant or award
Common Stock
+4,267$0.00$08,859Oct 24, 2025
Oct 23, 2025Mark A Wan
director
AGrant or award
Common Stock
+4,267$0.00$08,859Oct 24, 2025
Oct 23, 2025Abhinav Jain
director
AGrant or award
Common Stock
+4,267$0.00$07,312Oct 24, 2025
Oct 23, 2025Jill Marie Broadfoot
director
AGrant or award
Common Stock
+4,267$0.00$08,547Oct 24, 2025
Oct 23, 2025Marina Bozilenko
director
AGrant or award
Common Stock
+4,267$0.00$09,047Oct 24, 2025
Oct 23, 2025Adrian Adams
director
AGrant or award
Common Stock
+4,267$0.00$017,609Oct 24, 2025
Oct 23, 2025Marina Bozilenko
director
AGrant or award
Stock Option (Right to Buy)derivative
+25,600$0.00$025,600Oct 24, 2025
Oct 23, 2025Jill Marie Broadfoot
director
AGrant or award
Stock Option (Right to Buy)derivative
+25,600$0.00$025,600Oct 24, 2025
Oct 23, 2025Stephen J Hoffman
director
AGrant or award
Stock Option (Right to Buy)derivative
+25,600$0.00$025,600Oct 24, 2025
Oct 23, 2025Adrian Adams
director
AGrant or award
Stock Option (Right to Buy)derivative
+25,600$0.00$025,600Oct 24, 2025
Oct 23, 2025Abhinav Jain
director
AGrant or award
Stock Option (Right to Buy)derivative
+25,600$0.00$025,600Oct 24, 2025
Oct 23, 2025Mark A Wan
director
AGrant or award
Stock Option (Right to Buy)derivative
+25,600$0.00$025,600Oct 24, 2025
Oct 15, 2025Joseph Todisco
director
AGrant or award
Common Stock
+6,397$0.00$06,397Oct 16, 2025
Oct 15, 2025Joseph Todisco
director
AGrant or award
Director Stock Option (right to buy)derivative
+38,381$0.00$038,381Oct 16, 2025
May 20, 2025Shakil Aslam
Chief Medical Officer
FTax withholding
Commom Stock
-4,517$0.52$2,32948,178May 21, 2025
Apr 2, 2025Vincent J. Angotti
CHIEF EXECUTIVE OFFICER
POpen-market purchase
Common Stock
+213,310$0.59$125k403,769Apr 3, 2025
Apr 2, 2025Shakil Aslam
Chief Medical Officer
AGrant or award
Commom Stock
+15,000$0.00$052,695Apr 3, 2025
Apr 2, 2025Badri N Dasu
Chief Engineering Officer
AGrant or award
Common Stock
+15,000$0.00$042,011Apr 3, 2025
Apr 2, 2025Raffi Asadorian
Chief Financial Officer
AGrant or award
Common Stock
+15,000$0.00$047,214Apr 3, 2025
Apr 2, 2025Raffi Asadorian
Chief Financial Officer
AGrant or award
Stock Option (Right to Buy)derivative
+80,000$0.00$080,000Apr 3, 2025
Apr 2, 2025Vincent J. Angotti
CHIEF EXECUTIVE OFFICER
AGrant or award
Common Stock
+61,000$0.00$0474,769Apr 3, 2025
Apr 2, 2025Shakil Aslam
Chief Medical Officer
AGrant or award
Stock Option (Right to Buy)derivative
+80,000$0.00$080,000Apr 3, 2025
Apr 2, 2025Badri N Dasu
Chief Engineering Officer
AGrant or award
Stock Option (Right to Buy)derivative
+80,000$0.00$080,000Apr 3, 2025
Apr 2, 2025Vincent J. Angotti
CHIEF EXECUTIVE OFFICER
AGrant or award
Stock Option (Right to Buy)derivative
+365,000$0.00$0365,000Apr 3, 2025
Mar 31, 2025Nantahala Capital Management, LLC
owner, other
AGrant or award
Pre-Funded Warrantsderivativeindirect: See footnote
+4,266,211$0.59$2.5M11,510,601Apr 2, 2025
Jun 13, 2024Shakil Aslam
Chief Medical Officer
POpen-market purchase
Common Stock
+695$0.98$68132,695Feb 26, 2025
Jun 14, 2024Shakil Aslam
Chief Medical Officer
POpen-market purchase
Common Stock
+5,000$1.07$5,35737,695Feb 26, 2025
Feb 14, 2025Vincent J. Angotti
CHIEF EXECUTIVE OFFICER
FTax withholding
Common Stock
-10,575$0.67$7,085190,459Feb 18, 2025
Feb 14, 2025Badri N Dasu
Chief Engineering Officer
FTax withholding
Common Stock
-2,644$0.67$1,77127,011Feb 18, 2025
Feb 14, 2025Raffi Asadorian
Chief Financial Officer
FTax withholding
Common Stock
-3,245$0.67$2,17432,214Feb 18, 2025
Feb 10, 2025Raffi Asadorian
Chief Financial Officer
FTax withholding
Common Stock
-1,059$0.63$66736,519Feb 12, 2025
Feb 10, 2025Vincent J. Angotti
CHIEF EXECUTIVE OFFICER
FTax withholding
Common Stock
-3,515$0.63$2,214204,551Feb 12, 2025
Feb 10, 2025Badri N Dasu
Chief Engineering Officer
FTax withholding
Common Stock
-879$0.63$55430,535Feb 12, 2025
Feb 11, 2025Raffi Asadorian
Chief Financial Officer
FTax withholding
Common Stock
-1,060$0.62$65735,459Feb 12, 2025
Feb 11, 2025Vincent J. Angotti
CHIEF EXECUTIVE OFFICER
FTax withholding
Common Stock
-3,517$0.62$2,181201,034Feb 12, 2025
Feb 11, 2025Badri N Dasu
Chief Engineering Officer
FTax withholding
Common stock
-880$0.62$54629,655Feb 12, 2025
Dec 5, 2024Vincent J. Angotti
CHIEF EXECUTIVE OFFICER
POpen-market purchase
Common Stock
+5,000$0.64$3,200208,066Dec 6, 2024
Dec 2, 2024Raffi Asadorian
Chief Financial Officer
SOpen-market sale
Common Stock
-155$0.77$11937,578Dec 2, 2024
Nov 27, 2024Vincent J. Angotti
CHIEF EXECUTIVE OFFICER
POpen-market purchase
Common Stock
+5,000$0.73$3,650203,066Dec 2, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

TLPH insider trading: TALPHERA, INC. | InsiderTell